Busch and Malik appointed to the board of Bayer Schering Pharma

Published: 17-Jan-2007

The supervisory board of Bayer Schering Pharma has appointed Andreas Busch and Dr Kemal Malik to the company's Board of Management, effective February 1, 2007.


The supervisory board of Bayer Schering Pharma has appointed Andreas Busch and Dr Kemal Malik to the company's Board of Management, effective February 1, 2007.

Busch and Malik will also become members of the Bayer HealthCare executive committee.

Marc Rubin, currently a member of the Bayer Schering Pharma board of management responsible for r&d, is to leave the company by mutual consent, effective January 31, 2007. Rubin decided to resign from his position citing the impracticality, from both a business and a family perspective, of running the Germany-based organisation while based in the United States.

Rubin's present duties are to be split between the two new Board members. Busch will head up research, while Malik will assume responsibility for development.

You may also like